Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery.
Kathy S AlbainChristina YauEmanuel F PetricoinDenise M WolfJulie E LangAmy Jo ChienTufia C HaddadAndres Forero-TorresAnne M WallaceHenry G KaplanLajos PusztaiDavid M EuhusRita NandaAnthony D EliasAmy S ClarkConstantine GodellasJudy C BougheyClaudine IsaacsDebasish TripathyJanice LuRachel L YungRosa I GallagherJulia D WulfkuhleLamorna Brown SwigartGregor KringsYunn Yi ChenDavid A PotterErica M Stringer-ReasorSarah L BlairSmita M AsareAmy WilsonGillian L HirstRuby SinghraoMeredith BuxtonJulia L ClennellAshish SanilScott BerryAdam L AsareJeffrey B MatthewsAngela M DeMicheleNola M HyltonMichelle E MeliskoJane PerlmutterHope S RugoWilliam Fraser SymmansLaura van 't VeerDouglas YeeDonald A BerryLaura J EssermanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The Ang/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.